GlassScriptPhysician profile
Hugo Espinoza
NPI 1417207051
$12,501.54
in general payments reported to CMS, 2019-2025
10 companies · $10K in 2025
The $10K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $272 · 2022: $572 · 2023: $730 · 2024: $619 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $9,756 · Food and Beverage: $1,838 · Education: $62.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $9,755.89 |
| Food and Beverage | $1,838.20 |
| Education | $62.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11,289.20 | 2021-2025 | Invega Sustenna, Invega Trinza, Invega |
| Alkermes, INC. | $397.31 | 2021-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $144.54 | 2023-2025 | Ingrezza |
| Abbott Laboratories | $144.22 | 2025 | Cardiomems |
| Otsuka America Pharmaceutical, INC. | $140.09 | 2024 | Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $120.81 | 2023 | Uzedy |
| Amgen INC. | $107.73 | 2024 | Tavneos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.15 | 2025 | Caplyta |
| Lundbeck LLC | $33.99 | 2025 | Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $19.50 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugo Espinoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.